Ryan J Ice
California Pacific Medical Center
4 Papers
Ryan J Ice is an academic researcher from California Pacific Medical Center. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Hera Saqub,Hannah Proetsch-Gugerbauer,Vladimir Bezrookove,Mehdi Nosrati,Edith M Vaquero,David de Semir,Ryan J Ice,Sean D. McAllister,Liliana Soroceanu,Mohammed Kashani-Sabet,Robert W. Osorio,Altaf A. Dar +11 more
TL;DR: Dinaciclib is identified as a novel and potent therapeutic agent alone or in combination with gemcitabine for the treatment of CCA and produced a robust and sustained inhibition of tumor progression in vivo in a PDX mouse model, greater than either of the treatments alone.
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kevin B. Kim,Liliana Soroceanu,David de Semir,Sherri Z. Millis,Jeffrey S. Ross,Jeffrey S. Ross,Elham Vosoughi,Altaf A. Dar,Mehdi Nosrati,Pierre-Yves Desprez,Ryan J Ice,Michelle B. Chen,Kashish Chetal,Anukana Bhattacharjee,John Moretto,Stanley P. L. Leong,Mark I. Singer,Brian M. Parrett,David R. Minor,Sean D. McAllister,James R. Miller,Nathan Salomonis,Mohammed Kashani-Sabet +22 more
TL;DR: In this article, the authors compared the commercially available next-generation sequencing data from 84 patients with melanomas from their institution with a dataset of 1,986 patients as well as 1,088 patients profiled in cBioportal.
23
Durable multitransgene expression in vivo using systemic, nonviral DNA delivery
Chakkrapong Handumrongkul,Alice L. Ye,Stephen Chmura,Liliana Soroceanu,Marissa Mack,Ryan J Ice,Robert Thistle,Methawee Myers,Sarah Ursu,Yong Liu,Mohammed Kashani-Sabet,Timothy D. Heath,Denny Liggitt,David B. Lewis,Robert J. Debs +14 more
TL;DR: HEDGES can produce extended therapeutic levels of multiple transgene-encoded therapeutic human proteins from DNA inserts >1.5-fold larger than AAV-based therapeutics, thus creating combinatorial interventions to effectively treat common polygenic diseases driven by multigenic abnormalities.
17
Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies
Ryan J Ice,Michelle B. Chen,Max Sidorov,Tam Le Ho,Rinette Woo,Aida Rodriguez-Brotons,Tri Luu,Damon Jian,Kevin B. Kim,Stanley P. L. Leong,HanKyul Kim,Angela Kim,Des Stone,Ari Nazarian,Alyssia Oh,Gregory J. Tranah,Mehdi Nosrati,David de Semir,Altaf A. Dar,Stephen Chang,Pierre-Yves Desprez,Mohammed Kashani-Sabet,Liliana Soroceanu,Sean D. McAllister +23 more
TL;DR: The biological consistency observed between PDXCs and PDXs suggests thatPDXCs may allow for a rapid and comprehensive identification of treatments for aggressive cancers, including combination therapies.